Peptipedia
Weight LossFDA ApprovedFDA Approved

Semaglutide Oral

Also known as Rybelsus

The first oral GLP-1 receptor agonist FDA approved, using SNAC absorption enhancer. Achieves 80% bioavailability of subcutaneous injection.

FDA Approved - Type 2 diabetes
CompareFind Vendors

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

3-14 mg daily (titrate up)

Frequency

Daily

Duration

Long-term / chronic use

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 3-14 mg daily (titrate up) via Oral tablet on empty stomach with <4 oz water, Daily. Dose range: 3-14 mg daily. Duration: Long-term / chronic use.

Timing & Administration

Administer via Oral tablet on empty stomach with <4 oz water. Frequency: Daily.

Mechanism of Action

Same mechanism as injectable semaglutide but co-formulated with SNAC which enhances absorption across stomach lining.

Research Summary

Evidence level: fda approved. Clinical status: FDA Approved - Type 2 diabetes.

Side Effects & Safety

Important Warnings

  • BOXED WARNING: Thyroid C-cell tumors
  • Must be taken on empty stomach.
Nausea (up to 50%)
vomiting
diarrhea
constipation
pancreatitis
gallbladder problems

References

No references available.

Related Peptides

Browse all →
SemaglutideWeight Loss

A GLP-1 receptor agonist with multiple FDA approvals including weight management, type 2 diabetes treatment, cardiovascular risk reduction, and kidney disease protection. 94% amino acid similarity to human GLP-1.

View profile
TirzepatideWeight Loss

A dual GIP/GLP-1 receptor agonist representing next-generation incretin-based therapy, demonstrating superior weight loss outcomes compared to semaglutide in direct clinical comparisons.

View profile
LiraglutideWeight Loss

An FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management. The predecessor to semaglutide with daily dosing. 97% homology to native GLP-1.

View profile